Hyrolin Tablet 90 mg (Ticagrelor)

Adult dose

This drug should not be used concomitantly with other ADP receptor inhibitors (ticlopidine, clopidogrel, prasugrel). Acute coronary syndrome: Administer an initial dose of 180mg, followed by 90mg twice daily. Treatment is recommended for 12 months unless discontinuation of this drug is clinically necessary. Patients taking this drug should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. In patients with acute coronary syndrome who have an increased risk of bleeding and have undergone percutaneous coronary intervention (PCI), monotherapy with this drug (discontinuing aspirin) may be considered after 3 months of concomitant treatment with this drug and aspirin. (See 3. Patients Requiring Caution.) Patients with a history of myocardial infarction (occurring at least 1 year previously) who are at high risk of thrombotic cardiovascular events: Administer 60mg twice daily. Patients taking this drug should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. - Patients who were taking 90mg of this drug or another ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel) during the first year after myocardial infarction may continue treatment with 60mg of this drug. - Treatment with this drug may also be initiated in patients within 2 years after myocardial infarction or within 1 year after discontinuing a previous ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel). - The safety and efficacy of this drug were evaluated at 3 years of follow-up. Patients with type 2 diabetes who have undergone percutaneous coronary intervention (PCI) for coronary artery disease: Administer 60mg twice daily. Patients taking this drug should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. - For patients with acute coronary syndrome, refer to the relevant dosage and administration instructions. - Data on the safety and efficacy of this drug when used for more than 3 years are limited. Patients with acute ischemic stroke or high-risk transient ischemic attack: Administer an initial dose of 180mg, followed by 90mg twice daily for 30 days. Patients taking this drug should also receive a maintenance dose of aspirin (75 - 100mg), unless specifically contraindicated. An initial loading dose of aspirin (300-325mg) is recommended in patients with acute ischemic stroke or high-risk transient ischemic attack. Method of administration This drug is administered orally and may be taken with or without food. For patients who have difficulty swallowing tablets, crush this drug into a fine powder, disperse it in half a glass of water, and drink the mixture immediately. Rinse the cup used with half a glass of water and drink it again. This mixture may also be administered through a nasogastric tube (CH8 or larger); it is important to flush the nasogastric tube with water after administration. When switching from another antiplatelet drug to this drug, start this drug 24 hours after the last dose of the previous medication. If a dose is missed, take only 1 tablet (the next scheduled dose) at the next scheduled dosing time. Patients with renal impairment No dosage adjustment is necessary in patients with renal impairment. Patients with hepatic impairment No dosage adjustment is necessary in patients with mild hepatic impairment. This drug has not been studied in patients with severe hepatic impairment, and experience with its use in patients with moderate hepatic impairment is limited.

Child dose

Safety and efficacy have not been established in pediatric patients under 18 years of age (see “Other”).

This medication inhibits platelet aggregation in the blood and prevents thrombus formation. The risk of bleeding may increase, so it should not be used in patients with current bleeding or a history of intracranial hemorrhage. It is advisable to discontinue this medication at least 5 days prior to any scheduled surgery. During treatment, symptoms of bleeding such as nosebleeds, gum bleeding, hematuria, and easy bruising should be monitored closely. If bleeding is suspected, inform healthcare personnel immediately. Additionally, this medication can affect heart rhythm, therefore it should be administered cautiously in patients with bradycardia (slow heart rate) symptoms, and patients with asthma or chronic obstructive pulmonary disease should be particularly careful as breathing difficulties may occur. This medication should not be given to patients with severely impaired liver and kidney function, and caution should be exercised during co-administration with certain antibiotics or antivirals, as drug concentration may increase, raising the risk of side effects. Women who are pregnant or breastfeeding should consult healthcare professionals before taking this medication due to associated risks. Elderly patients or those with reduced kidney function should have regular kidney function tests while on this medication, as there may be an increase in uric acid levels or symptoms of gout. In cases of overdose, the risk of bleeding increases significantly, and as there is currently no antidote for this medication, appropriate treatment must be sought immediately. Patients should also be cautious when driving or operating machinery, as dizziness or confusion may occur during treatment. Finally, this medication should only be taken as prescribed by a physician, and patients should not change or stop the dose on their own.

• Hemorrhage
• intracranial hemorrhage
• ocular hemorrhage
• ear hemorrhage
• hypotension
• respiratory distress
• respiratory tract hemorrhage
• gastrointestinal hemorrhage
• diarrhea
• nausea

Store this medication in a tightly sealed container to protect it from air or moisture and keep it at room temperature between 1 to 30 degrees Celsius.

Appearance

Yellow, biconvex, round film-coated tablet

Package unit

30 tablets (10 tablets/PTP x 3)